Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin

Publisher： Karger

E-ISSN： 1423-0194|98|2|137-143

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.98, Iss.2, 2013-08, pp. : 137-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimizing Medical Therapy of Acromegaly: Beneficial Effects of Cabergoline in Patients Uncontrolled with Long-Acting Release Octreotide

By  

Neuroendocrinology, Vol. 90, Iss. 1, 2009-05 ,pp. : 82-92

Karger

Access to resources Recommend Favorite

Tumour Biology of Gastroenteropancreatic Neuroendocrine Tumours

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 8-11

Karger

Access to resources Recommend Favorite

Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line

By  

Neuroendocrinology, Vol. 87, Iss. 3, 2007-11 ,pp. : 168-181

Karger

Access to resources Recommend Favorite

Surgical Treatment of Endocrine Pancreatic Tumours

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 62-66

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours

By  

Neuroendocrinology, Vol. 105, Iss. 3, 2017-02 ,pp. : 255-265

Karger

Access to resources Recommend Favorite